Renal Cell Carcinoma

Our study demonstrated, downregulation of hsa-miR-200b-3p in ccRCC holds promise as a potential diagnostic biomarker and its identified target NDUFS1 as an independent prognostic biomarker for patients with ccRCC. These findings need to be validated in a large cohort of patients with RCC.

MMP9 serves as an independent prognostic factor in RCC. The enhanced computed tomography radiomics model composed of 3 features can noninvasively predict MMP9 expression levels in RCC patients.

Our findings reveal an intrinsic SLFN11-dependent vulnerability in ccRCC that synergizes with alkylating agents to induce an acquired PARP-1 dependency, thereby sensitizing BRCA1/2-WT tumors to PARP inhibition. Therefore, this work uncovers a potential therapeutic strategy for targeting SLFN11-high kidney cancers.

These nanoparticles exhibited optimal physicochemical properties, efficiently restored FDX1 palmitoylation, rescued CD8+ T cell function, and synergized with PD-1 blockade in preclinical RCC models without inducing systemic toxicity. Our findings uncover the iron-ZDHHC12-FDX1 axis as a metabolic checkpoint of T cell immunity and demonstrate a nanotechnology-based strategy to overcome iron-driven immunosuppression, offering translational potential for patients with iron-overloaded RCC.

Adjuvant immunotherapy has transformed the management of high-risk resected ccRCC, with pembrolizumab demonstrating improvements in DFS and OS...Additional biomarkers including sarcomatoid differentiation, specific genomic drivers (PBRM1, BAP1, VHL), circulating tumor DNA, epigenetic signatures, and systemic inflammatory markers, provide complementary insights into tumor biology and host-tumor interaction. Although none of these biomarkers are currently validated for routine clinical decision-making, integrative models combining clinicopathologic and molecular features may enable more precise selection of patients for adjuvant immunotherapy and help reduce overtreatment in localized ccRCC.

P2, N=50, Not yet recruiting, Jonsson Comprehensive Cancer Center

P1/2, N=111, Not yet recruiting, VM Discovery, Inc.

P2, N=62, Recruiting, City of Hope Medical Center | Not yet recruiting --> Recruiting | Initiation date: May 2026 --> Jan 2027

P=N/A, N=40000, Completed, London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's | Initiation date: Jul 1992 --> Apr 2002

P1, N=83, Active, not recruiting, HiFiBiO Therapeutics | Trial completion date: Dec 2025 --> Dec 2026 | Trial primary completion date: Dec 2025 --> Dec 2026

HIMT is rare and poses significant diagnostic challenges that often mimic other liver malignancies. This case report highlights the efficacy and safety of laparoscopic hepatectomy as both a diagnostic and therapeutic strategies.

Histopathological examination following radical nephrectomy with tumor thrombectomy demonstrated a pathological complete response. Diffuse programmed death-ligand 1 expression on pretreatment biopsy may have been associated with a favorable response to nivolumab plus ipilimumab.